NCT02531867View on ClinicalTrials.gov

Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Hypophosphatasia
Interventions
BIOLOGICAL

Asfotase Alfa

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY

NCT02531867 - Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan | Biotech Hunter | Biotech Hunter